Tag
This multicenter retrospective study shows that GLP-1 receptor agonists improve glycemic control and cardiometabolic parameters with good tolerance in heart transplant recipients with type 2 diabetes, supporting their therapeutic role in th
This study evaluates semaglutide’s benefits over dulaglutide or liraglutide among diabetic hemodialysis patients, highlighting improved survival, reduced hospitalizations, and greater weight loss with semaglutide.
This review synthesizes evidence on GLP-1 receptor agonist initiation impacting psychiatric hospitalisation and emergency visits in adults with schizophrenia and type 2 diabetes, highlighting metabolic and psychiatric interplay and therapeu
GLP-1 receptor agonists exhibit promising osteoprotective and anti-inflammatory effects in preclinical dental studies but lack robust clinical data, underscoring urgent research needs on their oral health impact and safety profile.
GLP-1 receptor agonists are increasingly used in women of reproductive age, but their safety during periconception and pregnancy remains unclear. Current observational data show no definitive harm, yet robust evidence is lacking, emphasizin
A French nationwide cohort study finds first-trimester exposure to second-line glucose-lowering agents, including GLP-1 receptor agonists, is generally safe for pregnancies with type 2 diabetes, though a slight increase in cardiac malformat
Semaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.
A comprehensive UK cohort study shows that GLP-1 receptor agonists do not reduce the incidence of obstructive sleep apnea compared to DPP-4 inhibitors in obese patients with type 2 diabetes.
This study investigates postoperative complication rates following body-contouring surgery among patients with differing weight-loss methods, revealing that weight-loss modality does not affect complications, while BMI and diabetes at surge
This study examines complication rates following body-contouring surgeries in patients after weight loss via bariatric surgery, GLP-1 receptor agonists, combination therapy, or lifestyle changes, finding modality-independent risk but highli
GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophren
This study evaluates complication rates following body contouring after weight loss via bariatric surgery, GLP-1 receptor agonists, combination therapy, and lifestyle changes, finding weight-loss modality does not affect postoperative compl
The gain-of-function GLP1R R131Q variant slows β-cell decline and improves glycemic response to GLP-1 receptor agonists, highlighting its potential role in precision diabetes therapeutics.
This study reveals a significant association between GLP-1 receptor agonist therapy and increased risk of smell and taste disturbances in type 2 diabetes patients, highlighting the need for awareness and monitoring.
This Swedish register-based study reveals that GLP-1 receptor agonists are associated with significantly reduced hospitalisations for alcohol and substance use disorders during treatment, with some lasting benefits after discontinuation of
This large multicenter study reveals that nonarteritic anterior ischemic optic neuropathy (NAION) patients exposed to GLP-1 receptor agonists exhibit similar optic disc crowding compared to nonexposed patients, with smaller cup-to-disc rati
A prespecified pooled analysis of three phase 3 trials including 30,787 participants found semaglutide reduced major kidney outcomes versus placebo, with a 16% relative risk reduction in the primary composite and a favourable safety profile across cardio-kidney-metabolic disease.
A large Swedish cohort study assesses whether glucagon-like peptide-1 receptor agonists increase the risk of anterior ischemic optic neuropathy in type 2 diabetes. Although a borderline elevated relative risk was observed, absolute incidenc
A large study in veterans with type 2 diabetes found that adding GLP-1 receptor agonists to basal insulin did not improve insulin discontinuation rates compared to SGLT-2 inhibitors or DPP-4 inhibitors over three years.
GLP-1 receptor agonists significantly reduce atherosclerosis progression, inflammatory biomarkers, and cardiovascular events independent of glycaemic control and obesity status, evidenced by robust preclinical and large-scale clinical data.
